Leverage biomaterials to modulate immunity for type 1 diabetes.
Leverage biomaterials to modulate immunity for type 1 diabetes.
复制标题
DOI:
10.3389/fimmu.2022.997287
复制
发表时间:
2022
影响因子:
7.3
通讯作者:
Zhang, Xudong
中科院分区:
文献类型:
--
作者:
Jing, Zhangyan;Li, Yuan;Ma, Yumeng;Zhang, Xiaozhou;Liang, Xin;Zhang, Xudong
The pathogeny of type 1 diabetes (T1D) is mainly provoked by the β-cell loss due to the autoimmune attack. Critically, autoreactive T cells firsthand attack β-cell in islet, that results in the deficiency of insulin in bloodstream and ultimately leads to hyperglycemia. Hence, modulating immunity to conserve residual β-cell is a desirable way to treat new-onset T1D. However, systemic immunosuppression makes patients at risk of organ damage, infection, even cancers. Biomaterials can be leveraged to achieve targeted immunomodulation, which can reduce the toxic side effects of immunosuppressants. In this review, we discuss the recent advances in harness of biomaterials to immunomodulate immunity for T1D. We investigate nanotechnology in targeting delivery of immunosuppressant, biological macromolecule for β-cell specific autoreactive T cell regulation. We also explore the biomaterials for developing vaccines and facilitate immunosuppressive cells to restore immune tolerance in pancreas.
登录
查看更多内容
影响因子:
9
作者:
Carabias P;Espelt MV;Bacigalupo ML;Rojas P;Sarrias L;Rubin A;Saffioti NA;Elola MT;Rossi JP;Wolfenstein-Todel C;Rabinovich GA;Troncoso MF
通讯作者:
Troncoso MF
影响因子:
3
作者:
Agardh, CD;Cilio, CM;Lernmark, Å
通讯作者:
Lernmark, Å
影响因子:
5.4
作者:
Battelino, Tadej;Bode, Bruce W.
通讯作者:
Bode, Bruce W.
DOI:
10.1111/j.1749-6632.1996.tb21144.x
发表时间:
1996-01-01
期刊:
ORAL TOLERANCE: MECHANISMS AND APPLICATIONS
影响因子:
--
作者:
Bergerot, I;Fabien, N;Thivolet, C
通讯作者:
Thivolet, C
影响因子:
5.1
作者:
Chang, Y;Yap, S;Trucco, M
通讯作者:
Trucco, M